Bif-1 suppresses breast cancer cell migration by promoting EGFR Endocytic degradation

Kristin B. Runkle, Cheryl L. Meyerkord, Neelam V. Desai, Yoshinori Takahashi, Hong Gang Wang

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Dysregulation of EGFR expression and signaling is well documented to contribute to disease progression and metastasis in many types of cancer including breast cancer. EGF-stimulated EGFR activation leads to receptor internalization and endocytic degradation to control EGFR-mediated signaling. This process is frequently deregulated in cancer cells, leading to increased EGFR expression and mitogenic signaling. Here, we demonstrate that Bif-1, a tumor suppressor, plays a role in EGFR endocytic degradation and chemotactic migration in MDA-MB-231 breast cancer cells. Our data reveal that suppression of Bif-1 expression delays EGFR degradation and sustains Erk1/2 activation in response to EGF stimulation. Mechanistically, loss of Bif-1 sequesters internalized EGF in Rab5-positive endosomes and delays EGFR trafficking to lysosomes. Recruitment of Rab7 to EGF-positive vesicles and the activation of Rab7 are impaired in Bif-1 knockdown cells. Additionally, intracellular pH and the localization of acidic vesicles are altered by suppression of Bif-1. Furthermore, inhibition of Bif-1 increases chemotactic cell migration in response to EGF or serum, which correlates with prolonged cytoskeletal reorganization. Importantly, the effect of Bif-1 on EGF-induced cell migration is abolished by gefitinib, an EGFR-specific inhibitor. Taken together, these data suggest a novel function for Bif-1 as a suppressor of breast cancer cell migration by promoting EGFR degradation through the regulation of endosome maturation.

Original languageEnglish (US)
Pages (from-to)956-966
Number of pages11
JournalCancer Biology and Therapy
Volume13
Issue number10
DOIs
StatePublished - Aug 1 2012

Fingerprint

Epidermal Growth Factor
Cell Movement
Breast Neoplasms
Endosomes
Lysosomes
Disease Progression
Neoplasms
Neoplasm Metastasis
Serum

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

Runkle, Kristin B. ; Meyerkord, Cheryl L. ; Desai, Neelam V. ; Takahashi, Yoshinori ; Wang, Hong Gang. / Bif-1 suppresses breast cancer cell migration by promoting EGFR Endocytic degradation. In: Cancer Biology and Therapy. 2012 ; Vol. 13, No. 10. pp. 956-966.
@article{b107c40fa662470b95f765ab71244dd0,
title = "Bif-1 suppresses breast cancer cell migration by promoting EGFR Endocytic degradation",
abstract = "Dysregulation of EGFR expression and signaling is well documented to contribute to disease progression and metastasis in many types of cancer including breast cancer. EGF-stimulated EGFR activation leads to receptor internalization and endocytic degradation to control EGFR-mediated signaling. This process is frequently deregulated in cancer cells, leading to increased EGFR expression and mitogenic signaling. Here, we demonstrate that Bif-1, a tumor suppressor, plays a role in EGFR endocytic degradation and chemotactic migration in MDA-MB-231 breast cancer cells. Our data reveal that suppression of Bif-1 expression delays EGFR degradation and sustains Erk1/2 activation in response to EGF stimulation. Mechanistically, loss of Bif-1 sequesters internalized EGF in Rab5-positive endosomes and delays EGFR trafficking to lysosomes. Recruitment of Rab7 to EGF-positive vesicles and the activation of Rab7 are impaired in Bif-1 knockdown cells. Additionally, intracellular pH and the localization of acidic vesicles are altered by suppression of Bif-1. Furthermore, inhibition of Bif-1 increases chemotactic cell migration in response to EGF or serum, which correlates with prolonged cytoskeletal reorganization. Importantly, the effect of Bif-1 on EGF-induced cell migration is abolished by gefitinib, an EGFR-specific inhibitor. Taken together, these data suggest a novel function for Bif-1 as a suppressor of breast cancer cell migration by promoting EGFR degradation through the regulation of endosome maturation.",
author = "Runkle, {Kristin B.} and Meyerkord, {Cheryl L.} and Desai, {Neelam V.} and Yoshinori Takahashi and Wang, {Hong Gang}",
year = "2012",
month = "8",
day = "1",
doi = "10.4161/cbt.20951",
language = "English (US)",
volume = "13",
pages = "956--966",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "10",

}

Bif-1 suppresses breast cancer cell migration by promoting EGFR Endocytic degradation. / Runkle, Kristin B.; Meyerkord, Cheryl L.; Desai, Neelam V.; Takahashi, Yoshinori; Wang, Hong Gang.

In: Cancer Biology and Therapy, Vol. 13, No. 10, 01.08.2012, p. 956-966.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Bif-1 suppresses breast cancer cell migration by promoting EGFR Endocytic degradation

AU - Runkle, Kristin B.

AU - Meyerkord, Cheryl L.

AU - Desai, Neelam V.

AU - Takahashi, Yoshinori

AU - Wang, Hong Gang

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Dysregulation of EGFR expression and signaling is well documented to contribute to disease progression and metastasis in many types of cancer including breast cancer. EGF-stimulated EGFR activation leads to receptor internalization and endocytic degradation to control EGFR-mediated signaling. This process is frequently deregulated in cancer cells, leading to increased EGFR expression and mitogenic signaling. Here, we demonstrate that Bif-1, a tumor suppressor, plays a role in EGFR endocytic degradation and chemotactic migration in MDA-MB-231 breast cancer cells. Our data reveal that suppression of Bif-1 expression delays EGFR degradation and sustains Erk1/2 activation in response to EGF stimulation. Mechanistically, loss of Bif-1 sequesters internalized EGF in Rab5-positive endosomes and delays EGFR trafficking to lysosomes. Recruitment of Rab7 to EGF-positive vesicles and the activation of Rab7 are impaired in Bif-1 knockdown cells. Additionally, intracellular pH and the localization of acidic vesicles are altered by suppression of Bif-1. Furthermore, inhibition of Bif-1 increases chemotactic cell migration in response to EGF or serum, which correlates with prolonged cytoskeletal reorganization. Importantly, the effect of Bif-1 on EGF-induced cell migration is abolished by gefitinib, an EGFR-specific inhibitor. Taken together, these data suggest a novel function for Bif-1 as a suppressor of breast cancer cell migration by promoting EGFR degradation through the regulation of endosome maturation.

AB - Dysregulation of EGFR expression and signaling is well documented to contribute to disease progression and metastasis in many types of cancer including breast cancer. EGF-stimulated EGFR activation leads to receptor internalization and endocytic degradation to control EGFR-mediated signaling. This process is frequently deregulated in cancer cells, leading to increased EGFR expression and mitogenic signaling. Here, we demonstrate that Bif-1, a tumor suppressor, plays a role in EGFR endocytic degradation and chemotactic migration in MDA-MB-231 breast cancer cells. Our data reveal that suppression of Bif-1 expression delays EGFR degradation and sustains Erk1/2 activation in response to EGF stimulation. Mechanistically, loss of Bif-1 sequesters internalized EGF in Rab5-positive endosomes and delays EGFR trafficking to lysosomes. Recruitment of Rab7 to EGF-positive vesicles and the activation of Rab7 are impaired in Bif-1 knockdown cells. Additionally, intracellular pH and the localization of acidic vesicles are altered by suppression of Bif-1. Furthermore, inhibition of Bif-1 increases chemotactic cell migration in response to EGF or serum, which correlates with prolonged cytoskeletal reorganization. Importantly, the effect of Bif-1 on EGF-induced cell migration is abolished by gefitinib, an EGFR-specific inhibitor. Taken together, these data suggest a novel function for Bif-1 as a suppressor of breast cancer cell migration by promoting EGFR degradation through the regulation of endosome maturation.

UR - http://www.scopus.com/inward/record.url?scp=84864538866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864538866&partnerID=8YFLogxK

U2 - 10.4161/cbt.20951

DO - 10.4161/cbt.20951

M3 - Article

C2 - 22785202

AN - SCOPUS:84864538866

VL - 13

SP - 956

EP - 966

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 10

ER -